Welcome to EQUITY DEVELOPMENT
The UK's longest established regulated provider of sponsored equity research.
We launched EQUITY DEVELOPMENT in 1997 becoming the first ever regulated provider of Sponsored Equity Research in the UK.
Our research teams are made up of expert analysts with deep understanding & experience in their sectors. Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).
We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.
Search for Company Research
FREE REGISTRATION
Sign up today and access the very latest company research
LOG IN
For access to all company research please
Deltex Medical
Deltex Medical Group Plc (Deltex Medical) is a medical technology company focused on the development, assembling and marketing of a minimally invasive, real-time cardiac function monitoring system, which uses Doppler (ultrasound) technology.
Progress in line with expectations
Sales up in all territories
Manufacturing capacity expanded
Profitability in line for 2010
Publication Date:
September 23 2008
Continuing to hit key milestones
Wide reimbursement granted for CardioQ in the US
CardioQ now standard for colorectal surgery at UCL and Guys and St. Thomas’
11 Spanish hospitals reviewing CardioQ, results expected H2
Fair value 39p per share vs current price 19.5p
Publication Date:
April 14 2008
Still moving forward
Sales significantly up in all territories
CardioQ received broad US reimbursement coverage
Growing recognition for reducing costs and improving surgery outcomes
Publication Date:
January 23 2008
US reimbursement granted
Reimbursement granted for CardioQ in the US
Coverage is broad and of unprecedented scale
Probe consumption increased significantly in US
Deltex's forecasts upgraded; fair value now 39p a share vs current 29p
Publication Date:
July 23 2007
Deltex; Oesophageal Doppler Monitoring recommended for reimbursement coverage in US
Since the beginning of this year Deltex Medical has posted a continuous stream of positive news. This was further evidenced yesterday with an announcement that the CMS (The Centers for Medicare and Medicaid Services) in the US is reconsidering the national coverage status of CardioQ.
Publication Date:
February 28 2007